Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-analysis

BMC Genetics

Lisa K Chopin¹  Hamdi Jarjanazi³  Inge Seim¹  Noel A Pabalan² 

[1]APCRC-Q, Queensland University of Technology, 37 Kent St., Woolloongabba, Brisbane 4102, Queensland, Australia

[2]Research Office, Saint Louis University, Baguio City 2600, Philippines

[3]Environmental Monitoring and Reporting Branch, Ontario Ministry of the Environment, 125 Resources Road, Etobicoke M9P 3 V6 2, ON, Canada

关键词: Cancer;    Polymorphisms;    GHSR;    GHRL;    Ghrelin;   

Others  :  1085339
DOI  :  10.1186/s12863-014-0118-3

 received in 2013-10-14, accepted in 2014-10-22,  发布年份 2014

【 摘 要 】

Background

There is growing evidence that the ghrelin axis, including ghrelin (GHRL) and its receptor, the growth hormone secretagogue receptor (GHSR), play a role in cancer progression. Ghrelin gene and ghrelin receptor gene polymorphisms have been reported to have a range of effects in cancer, from increased risk, to protection from cancer, or having no association. In this study we aimed to clarify the role of ghrelin and ghrelin receptor polymorphisms in cancer by performing a meta-analysis of published case–control studies.

We conducted searches of the literature published up to January 2013 in MEDLINE using the PubMed search engine. Individual data on 8,430 cases and 14,008 controls from six case–control studies of an all Caucasian population were evaluated for three ghrelin gene (GHRL; rs696217, rs4684677, rs2075356) and one ghrelin receptor (GHSR; rs572169) polymorphism in breast cancer, esophageal cancer, colorectal cancer and non-Hodgkins lymphoma.

Results

In the overall analysis, homozygous and recessive associations indicated that the minor alleles of rs696217 and rs2075356 GHRL polymorphisms conferred reduced cancer risk (odds ratio [OR] 0.61-0.78). The risk was unchanged for breast cancer patients when analysed separately (OR 0.73-0.83). In contrast, the rs4684677 GHRL and the rs572169 GHSR polymorphisms conferred increased breast cancer risk (OR 1.97-1.98, p = 0.08 and OR 1.42-1.43, p = 0.08, respectively). All dominant and co-dominant effects showed null effects (OR 0.96-1.05), except for the rs572169 co-dominant effect, with borderline increased risk (OR 1.08, p = 0.05).

Conclusions

This study suggests that the rs696217 and rs2075356 ghrelin gene (GHRL) polymorphisms may protect carriers against breast cancer, and the rs4684677 GHRL and rs572169 GHSR polymorphisms may increase the risk among carriers. In addition, larger studies are required to confirm these findings.

【 授权许可】

   
2014 Pabalan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Chopin LK, Seim I, Walpole CM, Herington AC: The ghrelin axis–does it have an appetite for cancer progression? Endocr Rev 2012, 33(6):849-891.
• [2]Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402(6762):656-660.
• [3]Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S: A role for ghrelin in the central regulation of feeding. Nature 2001, 409(6817):194-198.
• [4]Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR: Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001, 50(11):2540-2547.
• [5]Seim I, Amorim L, Walpole C, Carter S, Chopin LK, Herington AC: Ghrelin gene-related peptides: multifunctional endocrine/autocrine modulators in health and disease. Clin Exp Pharmacol Physiol 2010, 37(1):125-131.
• [6]Lorincz AM, Sukumar S: Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006, 13(2):279-292.
• [7]Waseem T, Javaid Ur R, Ahmad F, Azam M, Qureshi MA: Role of ghrelin axis in colorectal cancer: a novel association. Peptides 2008, 29(8):1369-1376.
• [8]Seim I, Lubik AL, Lehman M, Tomlinson N, Whiteside EJ, Herington A, Nelson C, Chopin L: Cloning of a novel insulin-regulated ghrelin transcript in prostate cancer. J Mol Endocrinol 2013, 50:1-14.
• [9]Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, Livingston DM: The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A 2004, 101(8):2357-2362.
• [10]Doecke JD, Zhao ZZ, Stark MS, Green AC, Hayward NK, Montgomery GW, Webb PM, Whiteman DC: Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers. Cancer Epidemiol Biomarkers Prev 2008, 17(4):1007-1012.
• [11]Dossus L, McKay JD, Canzian F, Wilkening S, Rinaldi S, Biessy C, Olsen A, Tjonneland A, Jakobsen MU, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Fournier A, Linseisen J, Lukanova A, Boeing H, Fisher E, Trichopoulou A, Georgila C, Trichopoulos D, Palli D, Krogh V, Tumino R, Vineis P, Quiros JR, Sala N, Martinez-Garcia C, Dorronsoro M, Chirlaque MD, Barricarte A, et al.: Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Carcinogenesis 2008, 29(7):1360-1366.
• [12]Feigelson HS, Teras LR, Diver WR, Tang W, Patel AV, Stevens VL, Calle EE, Thun MJ, Bouzyk M: Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res 2008, 10(4):R57. BioMed Central Full Text
• [13]Skibola DR, Smith MT, Bracci PM, Hubbard AE, Agana L, Chi S, Holly EA: Polymorphisms in ghrelin and neuropeptide Y genes are associated with non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1251-1256.
• [14]Wagner K, Hemminki K, Grzybowska E, Klaes R, Burwinkel B, Bugert P, Schmutzler RK, Wappenschmidt B, Butkiewicz D, Pamula J, Pekala W, Forsti A: Polymorphisms in genes involved in GH1 release and their association with breast cancer risk. Carcinogenesis 2006, 27(9):1867-1875.
• [15]Breslow NE, Day NE: Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.IARC Sci Publ 1987 82(ᅟ):1–406.
• [16]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
• [17]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
• [18]Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127(9):820-826.
• [19]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed 2003, 327(7414):557-560.
• [20]Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
• [21]Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
• [22]Ioannidis JP, Trikalinos TA: The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007, 176(8):1091-1096.
• [23]Campa D, Pardini B, Naccarati A, Vodickova L, Novotny J, Steinke V, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Gorgens H, Kotting J, Betz B, Kloor M, Engel C, Buttner R, Propping P, Forsti A, Hemminki K, Barale R, Vodicka P, Canzian F: Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case–control study. BMC Gastroenterol 2010, 10:112. BioMed Central Full Text
• [24]Ando T, Komaki G, Naruo T, Okabe K, Takii M, Kawai K, Konjiki F, Takei M, Oka T, Takeuchi K, Masuda A, Ozaki N, Suematsu H, Denda K, Kurokawa N, Itakura K, Yamaguchi C, Kono M, Suzuki T, Nakai Y, Nishizono-Maher A, Koide M, Murakami K, Nagamine K, Tomita Y, Ookuma K, Tomita K, Tonai E, Ooshima A, Ishikawa T, et al.: Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa. Am J Med Genet B Neuropsychiatr Genet 2006, 141B(8):929-934.
• [25]Gueorguiev M, Lecoeur C, Meyre D, Benzinou M, Mein CA, Hinney A, Vatin V, Weill J, Heude B, Hebebrand J, Grossman AB, Korbonits M, Froguel P: Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity. Obesity (Silver Spring Md) 2009, 17(4):745-754.
• [26]Ukkola O, Ravussin E, Jacobson P, Perusse L, Rankinen T, Tschop M, Heiman ML, Leon AS, Rao DC, Skinner JS, Wilmore JH, Sjostrom L, Bouchard C: Role of ghrelin polymorphisms in obesity based on three different studies. Obes Res 2002, 10(8):782-791.
• [27]Gahete MD, Cordoba-Chacon J, Hergueta-Redondo M, Martinez-Fuentes AJ, Kineman RD, Moreno-Bueno G, Luque RM, Castano JP: A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. PLoS One 2011, 6(8):e23302.
• [28]Jeffery PL, Murray RE, Yeh AH, McNamara JF, Duncan RP, Francis GD, Herington AC, Chopin LK: Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr Relat Cancer 2005, 12(4):839-850.
• [29]Seim I, Walpole C, Amorim L, Josh P, Herington A, Chopin L: The expanding roles of the ghrelin-gene derived peptide obestatin in health and disease. Mol Cell Endocrinol 2011, 340(1):111-7.
• [30]Lann D, LeRoith D: The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13(4):371-379.
• [31]Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC: Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 2011, 71(17):5754-5764.
• [32]Pollak M: Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 2008, 8(4):384-392.
• [33]Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M: Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011, 54(9):2254-2262.
• [34]Grossmann M, Wittert G: Androgens, diabetes and prostate cancer. Endocr Relat Cancer 2012, 19(5):F47-62.